LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

16.00 -0.12 (-0.74%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist

Price and Volume

Volume	890,002
Open	16.17
Bid (Size)	16.01 (100)
Ask (Size)	16.21 (100)
Prev. Close	16.12
Today's Range	15.78 - 16.18
52wk Range	15.70 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	90.12%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

December 01, 2025

Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZ

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-43.4%	-43.4%
1 Month	-47.4%	-47.4%
3 Month	-65.7%	-65.7%
6 Month	-46.8%	-46.8%
1 Year	-46.8%	-46.8%

More News

LENZ Therapeutics to Present at Upcoming Investor Conferences

November 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 05, 2025

Via Benzinga

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q3 2025 Revenue Beat and Progress on VIZZ Launch ↗

November 05, 2025

Via Chartmill

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

November 05, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

October 29, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

September 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Major Insider Sale Casts Shadow on LENZ Therapeutics' Valuation

September 27, 2025

Via MarketMinute

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

August 25, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

August 11, 2025

Via Benzinga

Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket ↗

August 11, 2025

Via Benzinga

LENZ Therapeutics' Eye Drop Scores First FDA Approval For Age-Related Blurred Vision Condition Impacting 128 Million People ↗

August 01, 2025

Via Benzinga

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

July 31, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Lenz (LENZ) Q2 Revenue Jumps 604% ↗

July 31, 2025

Via The Motley Fool

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

July 30, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

July 28, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

July 07, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

May 27, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 09, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 07, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

May 06, 2025

From LENZ Therapeutics, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

May 02, 2025

Via Benzinga

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 16.00

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 12/31/25 04:00 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 929.65M

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 930M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.